Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $143.00 at SVB Leerink

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price lowered by SVB Leerink from $144.00 to $143.00 in a research note issued to investors on Monday, Benzinga reports. SVB Leerink currently has a market perform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on ALNY. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an equal weight rating for the company in a research note on Friday, October 28th. The Goldman Sachs Group raised their price objective on Alnylam Pharmaceuticals from $239.00 to $270.00 and gave the company a buy rating in a research note on Friday, October 28th. Barclays lowered their price objective on Alnylam Pharmaceuticals from $240.00 to $236.00 and set an overweight rating for the company in a research note on Friday, October 28th. Jefferies Financial Group raised their price objective on Alnylam Pharmaceuticals from $218.00 to $232.00 and gave the company a buy rating in a research note on Monday, October 3rd. Finally, Canaccord Genuity Group assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 18th. They issued a buy rating and a $310.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $239.84.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $230.59 on Monday. The stock has a 50 day moving average of $226.99 and a 200 day moving average of $206.82. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $242.97. The firm has a market cap of $28.37 billion, a PE ratio of -23.60 and a beta of 0.50. The company has a current ratio of 3.48, a quick ratio of 3.33 and a debt-to-equity ratio of 3.85.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($1.46). Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative return on equity of 430.74%. The firm had revenue of $264.31 million for the quarter, compared to the consensus estimate of $291.81 million. During the same period in the previous year, the company posted ($1.72) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 40.9% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals will post -9.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Nuveen Asset Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 5,486.1% in the 3rd quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock valued at $3,321,309,000 after acquiring an additional 16,296,223 shares during the period. Lord Abbett & CO. LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $103,909,000. Point72 Asset Management L.P. purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $48,597,000. Eaton Vance Management increased its holdings in shares of Alnylam Pharmaceuticals by 606.7% in the 1st quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after acquiring an additional 262,893 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $43,377,000.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.